Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90%

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating potential violations of the federal securities laws by Tenax Therapeutics, Inc. (“Tenax” or the “Company”) (NASDAQ: TENX) following results from the Company’s Phase 3 LEVEL clinical trial of TNX-103.

On August 10, 2026, Tenax announced topline results from its Phase 3 LEVEL trial evaluating TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The Company disclosed that the trial failed to achieve statistical significance on its primary endpoint of improvement in six-minute walk distance compared with placebo and also failed to meet its key secondary endpoint.

Following the news, Tenax shares plummeted nearly 90% in intraday trading on August 10, 2026.

Johnson Fistel’s investigation concerns whether Tenax made materially misleading statements or failed to disclose material information to investors regarding the design of the LEVEL trial, the patient population enrolled in the study, and the likelihood that the trial would achieve its intended outcome.

The investigation is examining whether investors were adequately informed about the risk that LEVEL could enroll a materially different patient population than previously studied and whether Tenax’s prior statements concerning the trial’s design, patient enrichment, and prospects were misleading.

If you purchased or otherwise acquired Tenax Therapeutics securities and suffered a loss, you may contact Johnson Fistel to learn more about the investigation and your legal rights.

Click here to join the investigation.

For more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471. There is no cost or obligation to you.

About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investor Rights:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on U.S. exchanges. For more information about the firm and how we may be able to help you recover your losses, please visit www.johnsonfistel.com.

Achievements:
In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. The firm has recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel, marking the eighth time it has been recognized among the top U.S. plaintiffs' securities law firms.

Attorney Advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.

Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com